Learn More
BACKGROUND The ability to reduce the administration frequency of subcutaneous (SC) epoetin could provide benefits. This multicenter open-label study investigated the therapeutic equivalence of SC(More)
BACKGROUND Although the prevalence of chronic kidney disease (CKD) is 10–14%, several prospective studies note a low rate of progression to end-stage renal disease (ESRD) in stages 3 and 4. A correct(More)